Fig. 4: TFAP2A could markedly potentiate LUAD metastasis possibly by promoting EMT. | Cell Death & Disease

Fig. 4: TFAP2A could markedly potentiate LUAD metastasis possibly by promoting EMT.

From: TFAP2A potentiates lung adenocarcinoma metastasis by a novel miR-16 family/TFAP2A/PSG9/TGF-β signaling pathway

Fig. 4

A Cell migratory and invasive ability (left) by transwell assay as well as statistical analysis (right) for TFAP2A knockdown cell models of PC-9. B Cell migratory ability via wound-healing assay (left) and statistical analysis (right) for TFAP2A knockdown cell models of PC-9. C Fluorescence intensity detected in mice (left) and statistical analysis (right) for evaluation of vivo metastasis (five mice in each group). D H&E staining (left) and statistical analysis (right) for metastatic nodules in dissected lung specimen from mice (five mice in each group). E E-cadherin and N-cadherin protein levels for TFAP2A knockdown and overexpression cell models of PC-9 and H1650 respectively. F IHC staining for protein levels of TFAP2A, N-cadherin and E-cadherin in clinical specimens of LUAD (up, low resolution; down, high resolution). *p < 0.05; **p < 0.01; ***p < 0.001. N≥3, Data are presented as mean ± SD.

Back to article page